Thursday, October 06, 2022 12:12:06 PM
Tdr tweet. Just to add: some investors believed Revive was headed to a DSMB meeting first because of the ambiguous nature of last PR. IMO this PR shows that the company realizes it's more desirable to get a FDA consensus on EPs 1st, rather than deferring to the DSMB for a verdict. Agreed.
Just to add: some investors believed Revive was headed to a DSMB meeting first because of the ambiguous nature of last PR. IMO this PR shows that the company realizes it's more desirable to get a FDA consensus on EPs 1st, rather than deferring to the DSMB for a verdict. Agreed.
— The Dales Report (@TheDalesReport) October 6, 2022
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
